Álvaro Juárez Soto, MD, the chief of Urology Service at Hospital Universitario de Jerez, Cádiz, Spain, discusses the efficacy of apalutamide (Erleada) plus androgen deprivation therapy in patients with metastatic hormone-sensitive prostate cancer, as demonstrated in the phase 3 TITAN trial (NCT02489318).

Several key findings emerged from the TITAN trial, according to Juárez Soto. The study demonstrated the real-world effects of apalutamide vs placebo in terms of overall survival (OS), he explains. The OS at 24 months was 82.4% in the apalutamide cohort. The group also had a radiographic progression-free survival (PFS) of 68%, which translated to a 52% reduction in risk of radiographic PFS or death. Both measurements were the co-primary end points of the study, Juárez Soto concludes.

Videos

Álvaro Juárez Soto, MD, discusses the efficacy of apalutamide plus androgen deprivation therapy in patients with metastatic hormone-sensitive prostate cancer.



Dr. Juárez Soto on the Efficacy of Apalutamide Plus ADT in mHSPC

Álvaro Juárez Soto, MD, chief of Urology Service at Hospital Universitario de Jerez, Cádiz, Spain, discusses the rationale for examining apalutamide (Erleada) plus androgen deprivation therapy in patients with metastatic hormone-sensitive prostate cancer (mCSPC), as seen in the phase 3 TITAN study (NCT02489318).

Investigators behind the trial set out to demonstrate the safety and efficacy of apalutamide in a broad population of patients who had been diagnosed with mCSPC, according to Juárez Soto. Prior to the study, only high-risk patients with a high tumor volume benefitted from abiraterone acetate (Zytiga). The regimen is a new strategy that provides benefit to a broad population of patients, Juárez Soto concludes.

Álvaro Juárez Soto, MD, discusses the rationale for examining apalutamide plus androgen deprivation therapy in patients with metastatic hormone-sensitive prostate cancer, as seen in the phase 3 TITAN study. 

Dr. Juárez Soto on the Rationale for Apalutamide Plus ADT in mCSPC

Álvaro Juárez Soto, MD, chief, Urology Service, Hospital Universitario de Jerez, Cádiz, Spain, discusses the rationale to analyze the Latin American subgroup of patients with metastatic hormone-sensitive prostate cancer (mHSPC) evaluated in the phase 3 TITAN trial (NCT02489318). 

Findings from the interim analysis of the TITAN trial demonstrated improved overall survival and radiographic progression-free survival with the addition of apalutamide (Erleada) to androgen deprivation therapy (ADT) vs placebo plus ADT in men with mHSPC. 

Since geographical differences in disease presentation and management could exist in patients with mHSPC, a post-hoc analysis of the TITAN study evaluated the Latin American subgroup of patients treated on the trial, Juárez Soto says.

The results of the post-hoc analysis, which were presented in a virtual poster during week 2 of the 2021 AACR Annual Meeting, confirmed that the addition of apalutamide to ADT was beneficial for Latin American patients vs placebo plus ADT, Juárez Soto explains. Moreover, since no differences between this subgroup and the overall population were observed, apalutamide should be considered for a broad patient population, Juárez Soto concludes.

Álvaro Juárez Soto, MD, discusses the rationale to analyze the Latin American subgroup of patients with metastatic hormone-sensitive prostate cancer evaluated in the phase 3 TITAN trial.



Álvaro Juárez Soto, MD

Articles

Dr. Juárez Soto on the Efficacy of Apalutamide Plus ADT in mHSPC

Dr. Juárez Soto on the Rationale for Apalutamide Plus ADT in mCSPC

Dr. Juárez Soto on the Rationale to Analyze the Latin American Subgroup of the TITAN Trial in mHSPC